ECP
AGIO icon

Elk Creek Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Elk Creek Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$5.85M Sell
164,766
-2,156
-1% -$99.6K 1% 37
2019
Q4 		$7.97M Buy
+166,922
New +$6.31M 0.92% 48

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Elk Creek Partners's AGIO Position: Q1 2020 in Review

Elk Creek Partners reduced its Agios Pharmaceuticals (AGIO) stake by 1.3% in Q1 2020, selling an estimated $99.6K and leaving 164,766 shares worth $5.85M. The position accounts for 1% of the portfolio, ranked #37.

Elk Creek Partners first reported a position in AGIO in Q4 2019 and has held it in 2 quarters since. The position peaked at $7.97M in Q4 2019. 198 funds tracked by Wall St. Rank hold AGIO as of Q1 2020.

  • Elk Creek Partners held 164,766 shares of Agios Pharmaceuticals worth $5.85M as of Q1 2020.
  • Elk Creek Partners sold 2,156 Agios Pharmaceuticals shares in Q1 2020, an estimated $99.6K.
  • Agios Pharmaceuticals made up 1% of Elk Creek Partners's portfolio in Q1 2020, its #37 holding.
  • Elk Creek Partners first reported a position in Agios Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Elk Creek Partners's Agios Pharmaceuticals position peaked at $7.97M in Q4 2019.
  • 198 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.